Recent news on Oxymorphone

Penwest to Participate in Upcoming Conferences  -  May 18, 2007
PharmaLive.com (press release),The launch by Endo Pharmaceuticals in mid-2006 of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) formulated with the Company's TIMERx(R)

Penwest Reports First Quarter 2007 Financial Results  -  26 Apr 2007
PR Newswire (press release),The launch by Endo Pharmaceuticals in mid-2006 of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) formulated with the Company's TIMERx(R)

Penwest Confirms Patent and Trademark Office Action on Oxymorphone ...  -  Mar 28, 2007
Drug Newswire (press release),This is one of several patent applications that Penwest is currently prosecuting related to Opana(R) ER (oxymorphone HCl) extended-release tablets CII,

Penwest First Quarter 2007 Financial Results Conference Call  -  Apr 12, 2007
PR Newswire (press release),The launch by Endo Pharmaceuticals in mid-2006 of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) formulated with the Company's TIMERx(R)

Oxymorphone Extended-Release Appears Effective in Treating ...  -  Feb 14, 2007
DG NewsNEW ORLEANS, LA -- February 14, 2007 -- Patients living with moderate to severe chronic lower back pain appear to respond well to treatment with oxymorphone

Penwest Fourth Quarter and Year End 2006 Financial Results ...  -  Feb 15, 2007
PR Newswire (press release),The launch by Endo Pharmaceuticals of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) in mid-2006 demonstrates the execution of this

Penwest To Participate In Upcoming Conferences  -  Feb 22, 2007
PR Newswire (press release),The launch by Endo Pharmaceuticals of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) in mid-2006 demonstrates the execution of this

Endo and Penwest Agree to Amend Opana(R) ER Contract  -  Jan 8, 2007
Drug Newswire (press release),The launch by Endo Pharmaceuticals of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) in mid-2006 demonstrates the execution of this

Positive Results From Two Phase 3 Clinical Trials of Fentora(TM ...  -  Jan 9, 2007
DG NewsSchedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of

Penwest to Participate In Upcoming Conferences  -  Nov 28, 2006
Drug Newswire (press release),The launch by Endo Pharmaceuticals of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) in mid-2006 demonstrates the execution of this

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional